P3H4 and PLOD1 expression associates with poor prognosis in bladder cancer

Zhang, Junjie; Dong, Yun; He, Hong; Chen, Jiangang; Zhang, Shaoqi; Wu, Wei; Zhang, Qianjin; Han, Conghui; Hao, Lin

doi:10.1007/s12094-022-02791-1

Cited by 7 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It reported that P3H4 was highly expressed in BC tissues, and knockdown P3H4 expression not only inhibited BC cell proliferation, cell cycle, migration and invasion, and also inhibited BC growth ( Hao et al, 2020 ). It was confirmed that P3H4 expression associates with poor prognosis in bladder cancer ( Zhang et al, 2022 ). Previous studies have shown that PDIA6 is overexpressed in BC tissues and cell lines.…”

Section: Discussionmentioning

confidence: 83%

Hub gene associated with prognosis in bladder cancer is a novel therapeutic target

Fang

et al. 2023

PeerJ

View full text Add to dashboard Cite

Objective Bladder cancer is a clinical and social conundrum due to its high incidence and recurrence rate. It is urgent to find new targets for the diagnosis and treatment of bladder cancer and improve the prognosis and survival rate of bladder cancer patients. We sought a prognosis-related gene, built related models of evaluated bladder cancer and identified the function of the hub gene in bladder cancer. Methods We downloaded the data of bladder cancer patients from the TCGA database, and used differentially expressed genes (DEGs), copy number variation (CNV) and survival analysis to scan the hub genes associated with prognosis in bladder cancer. Then, multi-factor cox regression was used to obtain the bladder cancer prognosis correlation model. Then, we analyzed the relationship between the expression of hub gene and immune microenvironment of bladder cancer. The relationship between the expression of hub gene and prognosis in bladder cancer patients was verified by immunohistochemistry. Cell proliferation assay and drug sensitivity test in vivo were used to verify the inhibition of bladder cancer by targeted inhibitors. Results In bladder cancer, we screened seven hub genes (ACLY, CNP, NKIRAS2, P3H4, PDIA6, VPS25 and XPO1) associated with survival. Moreover, the multifactor regression model constructed with hub gene can well distinguish the prognosis of bladder cancer. Hub gene is mostly associated with immune microenvironment. Immunohistochemical results basically confirmed the importance of XPO1 in bladder cancer. Selinexor (an inhibitor of XPO1) could effectively inhibit the proliferation of bladder cancer in the cell proliferation experiments by CCK-8 assays and it could suppress the growth of bladder cancer in mouse bladder cancer model. Conclusions In this study, a prognostic model with seven hub genes has provided great help for the prognosis prediction of bladder cancer patients. And XPO1 is an important target affecting the prognosis of bladder cancer, and inhibition of XPO1 can effectively inhibit bladder cancer proliferation and growth.

show abstract

Section: Discussionmentioning

confidence: 83%

Hub gene associated with prognosis in bladder cancer is a novel therapeutic target

Fang

et al. 2023

PeerJ

View full text Add to dashboard Cite

show abstract

“…P3H4 has been identified in various cancers. P3H4 promoted cell proliferation, cell cycle, migration and invasion in the bladder [12] and was associated with poor prognosis in bladder cancer [13]. Comtesse et al reported that patients with meningioma carry antibodies against P3H4, which may represent a new diagnostic and therapeutic target in meningioma [14].…”

Section: Introductionmentioning

confidence: 99%

P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR

Chen

Liang

Huang³

et al. 2022

Cancers

View full text Add to dashboard Cite

Lung cancer is associated with the greatest number of cancer-related deaths worldwide. Lung adenocarcinoma (LUAD) accounts for 85% of all cases of lung cancer. Despite recent advances in treatment, the 5-year survival rate remains less than 15%. Thus, the diagnostic and therapeutic role of LUAD remain to be further studied. The prolyl 3-hydroxylase family member 4 (P3H4) is involved in various cancers, but little is known about its role in LUAD. Our study demonstrated that the P3H4 gene was upregulated in LUAD. Clinically, the expression of P3H4 was positively correlated with an advanced TNM stage and shorter survival. Functionally, P3H4 plays a significant role in the metastasis and proliferation of LUAD both in vitro and in vivo. Mechanistically, P3H4 might interact with EGFR to regulate the metabolic substances. Our study indicated that P3H4 is a critical gene in the malignant progression of LUAD and represents a potential biomarker and therapeutic target.

show abstract

“…P3H4 is an autoantigen associated with several types of human diseases, including cancers [ 22 , 23 ]. Our previous studies showed that the expression level of P3H4 was upregulated in BC tumor tissues compared with non-tumor tissues [ 21 , 24 ]. We found that BC patients with high expression levels of P3H4 had lower ratios of disease-free survival and overall survival compared with patients who had low levels of P3H4 [ 21 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

“…Our previous studies showed that the expression level of P3H4 was upregulated in BC tumor tissues compared with non-tumor tissues [ 21 , 24 ]. We found that BC patients with high expression levels of P3H4 had lower ratios of disease-free survival and overall survival compared with patients who had low levels of P3H4 [ 21 , 24 ]. Experiments based on both in vitro and in vivo experimental models indicated that the knockdown of P3H4 by siRNA inhibited BC cell proliferation and tumor growth [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Efficient Delivery of P3H4 siRNA and Chlorin e6 by cRGDfK-Installed Polyarginine Nanoparticles for Tumor-Targeting Therapy of Bladder Cancer

et al. 2022

View full text Add to dashboard Cite

Purpose: Prolyl 3-hydroxylase family member 4 (P3H4) is a potent prognostic oncogene in bladder cancer (BC), and the inhibition of P3H4 suppresses BC tumor growth. This study aimed to evaluate the efficiency of P3H4 inhibition for BC tumor therapy via tumor-targeting nanoparticles. Methods and results: A linear polyarginine peptide (R9) was synthesized, azide-modified, and then assembled with cyclic pentapeptide cRGDfK. Chlorin e6 (ce6)-conjugated CH3-R9-RGD nanoparticles were prepared for the delivery of siP3H4 into T24 cells in vitro and BC tumors in vivo. Dynamic light scattering analysis identified that the optimum CH3-R9-RGD@siP3H4 molar ratio was 30/1. CH3-R9-RGD@ce6/siP3H4 nanocomposites decreased P3H4 expression and cell proliferation and promoted reactive oxygen species production, apoptosis, and calreticulin exposure in T24 cells in vitro. In vivo experiments showed that CH3-R9-RGD@ce6/siP3H4 nanocomposites caused pathological changes, suppressed BC tumor growth, promoted caspase 3 expression, and enhanced calreticulin exposure in tumor cells. Conclusions: The tumor-targeting CH3-R9-RGD nanocomposites encapsulating siP3H4 and ce6 might be an alternative therapeutic strategy or intravesical instillation chemotherapy for BC.

show abstract

P3H4 and PLOD1 expression associates with poor prognosis in bladder cancer

Cited by 7 publications

References 29 publications

Hub gene associated with prognosis in bladder cancer is a novel therapeutic target

Hub gene associated with prognosis in bladder cancer is a novel therapeutic target

P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR

Efficient Delivery of P3H4 siRNA and Chlorin e6 by cRGDfK-Installed Polyarginine Nanoparticles for Tumor-Targeting Therapy of Bladder Cancer

Contact Info

Product

Resources

About